Cullinan Therapeutics, Inc. · NASDAQ:CGEM

Cullinan Therapeutics — Cullinan Oncology — Technical Presentation (December 2021)

18 slides from Cullinan Therapeutics's technical presentation, Dec 16, 2021

  1. Slide 1: Mining for Tomorrow's Cures: CLN-081 Clinical Update

    Exhibit 99.2 Mining for Tomorrow’s Cures CLN-081 Clinical Update December 2021

  2. Slide 2: Important Notice and Disclaimers

    Important Notice and Disclaimers This presentation contains forward-looking statements of Cullinan Oncology, Inc. (“Cullinan,” “we” or “our”). These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan’s beliefs and expectations regarding our p

  3. Slide 3: Executive hosts of today's webinar

    Executive hosts of today’s webinar Nadim Ahmed Jon Wigginton, MD Chief Executive Officer Senior Advisor & Chairman of SAB Leigh Zawel, PhD Jeff Trigilio Chief Scientific Officer, Chief Financial Officer Small Molecules 3

  4. Slide 4: Advancing a broad pipeline of targeted cancer therapeutics

    Cullinan Oncology: Advancing a broad pipeline of targeted cancer therapeutics Discovery / IND- Program (Subsidiary/Project) Lead Phase 1 Phase 2 Phase 3 Enabling Modality / MOA Optimization CLN-081 (Pearl) NSCLC EGFRex20 EGFR ex20 inhibitor ➢ Strategy to select programs with CLN-049 (Florentine) r /

  5. Slide 5: CLN-081 Clinical update highlights

    CLN-081 Clinical update highlights Data Summary Status Efficacy Safety ▪ High response rate in ▪ Nominated RP2D of ▪ Favorable safety and larger number of patients 100mg BID tolerability profile ▪ Durable responses and encouraging PFS CLN-081: A differentiated clinical profile 5

  6. Slide 6: CLN-081: Selective EGFR inhibitor for NSCLC patients with exon 20 mutations

    CLN-081: Selective EGFR inhibitor for NSCLC patients with exon 20 mutations CLN-081: Unique design properties Select CLN-081 pre-clinical data Selectivity Index IC50 WT/mutant LXF2478 PDX model for lung cancer High harboring EGFR V769_D770INSASV Distinct selectivity chemical HER2- to mutant scaffold

  7. Slide 7: CLN-081 Phase 1/2a trial design

    CLN-081 Phase 1/2a trial design Patient Enrollment Accelerated Phase 1 Phase 2a Dose (BID) Rolling 6 Titration Expansion Expansion N = 2 N = 6 30 mg ➢ 36 patients enrolled in Phase 1/2a at 100 mg BID N = 1 45 mg ➢ Expanded enrollment at 150 mg BID stopped after N = 1 N = 6 N = 7 65 mg 11 patients ba

  8. Slide 8: Heavily pretreated patient population including prior EGFR TKI or immunotherapy

    Heavily pretreated patient population including prior EGFR TKI or immunotherapy Select Baseline Characteristics Characteristic All patients (n=73) Median age (range) 64 (36-82) ➢ Heavily pretreated population Number of prior systemic anticancer regimens ➢ Over 65% of patients with 2 or more prior li

  9. Slide 9: Differentiated safety and tolerability profile of CLN-081 at proposed RP2D

    Differentiated safety and tolerability profile of CLN-081 at proposed RP2D Dose (BID) 100 mg 150 mg Overall Safety Population (n, %) 39 11 73 100 mg BID nominated as RP2D Grade 1 TRAE of interest Skin Rash 21 (54) 4 (36) 38 (52) At 100 mg BID (N=39): Diarrhea 10 (26) 1 (9) 14 (19) ➢ No Gr ≥3 rash/di

  10. Slide 10: PK profile consistent with clinical safety profile

    PK profile consistent with clinical safety profile Average Unbound Plasma Concentration over Time 1000 ➢ CLN-081 PK well-behaved to date GI -WT EGFR 50 ➢ Sustained PK exposure over GI50 for ex20ins 100 EGFR for 8h post dose GI -Ex20insASV 50 GI -Ex20insSVD ➢ Limited time of exposure 50 over GI50 for

  11. Slide 11: Encouraging response rate in expanded cohort at RP2D

    Encouraging response rate in expanded cohort at RP2D 100 mg BID 150 mg BID Overall Response (n=36), RP2D (n=11) (n=70) Best Response, n (%) PR (Confirmed) 14 (39) 3 (27) 25 (36) PR (Pending) 1 (3) -- 1 (1) PR (Unconfirmed) 3 (8) 2 (18) 7 (10) Stable Disease (SD) 17 (47) 5 (45) 34 (49) Progressive Di

  12. Slide 12: Durable objective responses and extended stable disease in patients treated at 100mg BID

    Durable objective responses and extended stable disease in patients treated at 100 mg BID 100mg BID Cohort: Duration of Treatment (Months) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 N771delinsGY Pending NGS D770_N771insSVD D770_N771insSVD D770_N771insY Pending NGS D770_N771insSVD D770_N771ins

  13. Slide 13: Tumor regression observed in majority of patients treated at 100mg BID

    Tumor regression observed in majority of patients treated at 100 mg BID 100mg BID Cohort: % Δ from Baseline in Target Lesions 100% ➢ Tumor regression observed in 33/36 (92%) treated patients 80% ➢ Patients respond post EGFR TKI (E) or post checkpoint inhibitor (C) 60% 40% 20% E * 0% E E * C C C -20%

  14. Slide 14: CLN-081 acts rapidly: Tumor regression in 86% of patients at first assessment

    CLN-081 acts rapidly: Tumor regression in 86% of 100mg BID patients at first assessment 100mg BID Cohort: Change from baseline (sum of target lesions) 100% 80% 60% 40% 20% 0% -20% -40% -60% -80% -100% 0 42 105 168 231 294 357 420 483 Days First on-treatment scan 14 % Change from Baseline (Sum of Leg

  15. Slide 15: Durability profile building for patients treated at RP2D

    Durability profile building for patients treated at RP2D Phase 1 Patients at 100 mg BID (n = 13) *Duration of Response, Median >15 months *Progression Free Survival, Median 12 months **Disease Control Rate 92% * Based upon Kaplan-Meier estimates ** Disease control rate (DCR): % of patients with stab

  16. Slide 16: Disease control rates based on baseline CNS status

    Disease control rates in patients treated at 100 mg BID based on baseline CNS status Phase 1 Patients at 100 mg BID* Disease Control Rate (DCR)**, All (N=13) 92% ➢ CNS Disease History at Baseline (N=4) 100% ➢ No CNS Disease History at Baseline (N=9) 89% * Patients with stable, treated brain metastas

  17. Slide 17: CLN-081 Conclusions and next steps

    CLN-081 Conclusions and next steps • Updated data at the proposed RP2D of 100 mg BID, reaffirms differentiated clinical profile for CLN-081 (an oral TKI) Summary • High response rate maintained with expanded patient numbers at RP2D • Durable responses and encouraging PFS • Antitumor activity across

  18. Slide 18: Q&A

    Nadim Ahmed Jon Wigginton, MD Chief Executive Officer Senior Advisor & Chairman of SAB Q&A Leigh Zawel, PhD Jeff Trigilio Chief Scientific Officer, Small Molecules Chief Financial Officer

Cullinan Oncology — Technical Presentation (December 2021) on 6ix